Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gout imaging showdown: ultrasound vs. DECT in 60 patients

NCT ID NCT03162341

Knowledge-focused Sponsor: Lille Catholic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well two types of imaging—ultrasound and dual-energy CT (DECT)—agree when measuring urate crystal deposits in people with gout. Sixty adults starting urate-lowering therapy were scanned at the start and again after 6, 12, and 24 months. The goal was to see if the two methods give similar results for tracking changes in deposit size over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Aug 2017

Finished

Nov 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of gout based on the ACR/EULAR 2015 criteria * uricemia ≥6 mg/dL * warranted introduction of urate-lowering therapy according to the ACR 2012 or EULAR 2016 criteria * signature of the informed consent * social insurance affiliation Exclusion Criteria: * pregnancy or breastfeeding * patient under legal guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gout

Contacts and locations

Locations

  • Bichat Hospital

    Paris, 75018, France

  • Hospital Group of the Catholic Institute

    Lomme, 59462, France

  • Lariboisière Hospital

    Paris, 75475, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.